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Abstract Natural killer (NK) cells are lymphocytes that
play an important role in anti-tumour immunity. Their
potential against brain cancer has been demonstrated
in vitro and in vivo, both as a direct anti-tumour agent and
in experimental therapies stimulating endogenous NK cell
cytotoxicity. However, the clinical translation of these
promising results requires detailed knowledge about the
immune status of brain tumour patients, with focus on the
NK cell population. In this report, we provide an overview
of the studies investigating NK cell infiltration into the
tumour, emphasizing the need of revision of the method-
ologies and further research in this field. We also discuss
the potential of using autologous or allogeneic NK cells as
effector cells in cellular therapy against brain cancer and
developing immunotherapies stimulating endogenous NK
cell-mediated anti-tumour response, such as blocking
inhibitory killer immunoglobulin-like receptors. Combi-
nation of NK cell adoptive transfer with targeted therapies,
such as anti-EGFR therapeutic antibody (CetuximAb)
could also be a potent strategy.
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Abbreviations
ADCC Antibody dependent cellular cytotoxicity
APC Antigen presenting cell
BBB Blood brain barrier
CpG-ODN CpG-oligodeoxynucleotides
CTL Cytotoxic T lymphocyte
DC Dendritic cell
EGFR Epidermal growth factor receptor
GBM Glioblastoma
GvL Graft versus leukemia (effect)
HLA Human leukocyte antigen
IFN-c Interferon gamma
IHC Immunohistochemistry
IL Interleukin
KIR Killer immunoglobulin-like receptors
LAK cells Lymphokine activated killer cells
MHC Major histocompatibility complex
MRI Magnetic resonance imaging
NCR Natural cytotoxicity receptor
NK cells Natural killer cells
PBMCs Peripheral blood mononuclear cells
rAAV2 Recombinant adeno-associated virus 2
SLMC Spontaneous lymphocyte mediated cytotoxicity
TGFb Transforming growth factor-beta
TLR Toll-like receptor
Introduction: why focus on natural killer cells for brain
tumours?
Brain tumours are intracranial neoplasms located in the
brain and meninges (excluding haematopoietic malignan-
cies occurring in the brain) and they account for approxi-
mately 1.4 % of all cancers [1, 2]. The incidence of brain
and central nervous system tumours worldwide in 2008
was 237,913 new reported cases and is projected to
increase to 357,377 by 2030 [3]. Depending on the grade of
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malignancy, the current standard treatment includes sur-
gery, chemo- and/or radiotherapy. Despite advances in
anti-tumour therapy, patients’ outcomes remain poor due to
inevitable recurrence and malignant progression. One of
the challenges in treating brain tumours is the presence
of the blood brain barrier (BBB) that limits the access of
systemically administered drugs into the tumour site. Due
to the BBB, lack of lymphatic drainage and lack of pro-
fessional antigen presenting cells, brain tumours have been
also considered protected from immune system surveil-
lance. However, this concept has been revised, as immune
cells have been shown to infiltrate brain tumours [4] and
play important roles in both anti-tumour immunity [4] and
tumour progression [5, 6].
Natural killer (NK) cells are large granular lymphocytes
of the innate immune system. These cells are able to
directly lyse infected or transformed cells without specific
immunization [7]. NK cells can also recognise the Fc part
of antibodies via low affinity FccRIIIA (CD16) receptor
and perform antibody dependent cellular cytotoxicity
(ADCC) of antibody-coated cells [8]. Moreover, they
secrete various cytokines and chemokines, such as inter-
feron gamma (IFN-c) [7]. The recognition of target cells
and activation of NK cells is controlled by a balance
between activating and inhibitory signals mediated by
binding of the ligands expressed on target cells to the
receptors expressed on NK cells [9, 10]. The inhibitory
receptors include NKG2A [11] and inhibitory killer
immunoglobulin-like receptors (KIRs) [12, 13] that rec-
ognise major histocompatibility complex (MHC) class I
molecules, which are often down regulated on virus-
infected or tumour cells. The activating signals are medi-
ated by natural cytotoxicity receptors (NCRs) [14] and
NKG2D [14] that recognise ligands expressed on infected
or transformed cells, but absent on most normal cells.
Some KIR receptors also mediate activating signals,
however, they engage the MHC class I ligands with lower
affinity than inhibitory KIRs [15]. Upon activation, NK
cells induce apoptosis of target cells by secreting granules
containing perforin and granzymes [16] or by signalling via
death receptors [17].
NK cells play an important role in anti-tumour immunity
as several lines of evidence link NK cell surveillance [18],
anti-tumour activity [19] and prognostic significance [20–
24] in various types of cancers. The potential of NK cells
as effectors against brain tumours has been demonstrated
in vitro [25, 26] and in vivo [27, 28, 29]. However,
translating these promising results into the clinic requires
answers to several important questions related to patients’
immune status: (1) Do NK cells infiltrate brain tumours and
if yes, are they functional? (2) What is the prognostic
significance of NK cells’ activity and their infiltration into
the tumour? (3) How do the tumour cells escape NK
cell-mediated surveillance and killing? Clinical trials using
NK cells against brain tumours have already been con-
ducted [30] and some are in progress or recently completed
(for example clinicaltrials.gov: NCT00823524 and
NCT00909558). Moreover, other experimental therapies
might be influenced by patients’ NK cell activity [31] and
also several treatment strategies have been shown to
stimulate NK cell-mediated lysis of tumour cells [8, 27, 28,
32]. Therefore, it is of great importance to take into con-
sideration the brain tumour patients’ immune status and
encourage further research in this direction. Our review
summarizes what is already known in this field and what
aspects need further investigation. We also provide an
overview of pre-clinical studies conducted and discuss the
clinical application of NK cell-based therapy.
What is the immune status of brain tumour patients?
Numerous studies have investigated the immune system of
brain tumour patients, mainly in the context of malignant
glioma. Brain tumour patients suffer from extensive
immunosuppression due to lymphopenia, decreased lym-
phocyte proliferation [33, 34] and diminished cytotoxic
activity [35], reduced MHC class I expression on mono-
cytes [33, 34] and predominance of anti-inflammatory
T-helper 2-type (Th2) cytokine production [33]. In one of
the first studies, Servadei et. al analysed cytotoxic func-
tionality of peripheral blood lymphocytes isolated from
anaplastic glioma patients and compared with those from
bladder and kidney cancer patients and healthy donors [35].
In all three types of cancers they observed decreased
ADCC and decreased spontaneous lymphocyte mediated
cytotoxicity (SLMC) when comparing to healthy donors, to
the greatest extent in anaplastic glioma patients. Reports
investigating NK cell numbers and activity in the periph-
eral blood of glioma patients show conflicting results
(reviewed in Dix et al. [33]. The functionality of circulating
NK cells is often affected in brain tumour patients and it
may result from immunosuppressive factors released by
tumour cells. An example is transforming growth factor-
beta (TGFb) that down-regulates the expression of NKG2D
activating receptor on NK cells isolated from glioblastoma
patients compared to those from meningioma patients [36].
Another important factor to be considered is the influence
of the standard treatment. Brain tumour patients are
immune-compromised due to treatment with steroids [37].
Moreover, decreased absolute numbers of NK cells have
been observed in the blood of glioblastoma patients
receiving concomitant radiation therapy and temozolo-
mideTM [38].
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Do NK cells infiltrate the brain tumour?
The remaining question was whether the NK cells infiltrate
the tumour site. In 1988, Stevens et al. characterised the
immune infiltrates in gliomas, carcinoma metastases, cra-
niopharyngiomas and meningiomas [39]. To identify NK
cells within the brain tumour tissue, the immunohisto-
chemistry (IHC) technique with Leu7 (CD57) and Leu11b
(CD16) antibodies was used (Table 1). They observed that
in most glioma cases NK cells were absent, while carci-
noma metastases and craniopharyngiomas were more fre-
quently infiltrated by NK cells. Single NK cells were
detected in some meningiomas. In all cases, NK cells
constituted a minor fraction among all immune cells
infiltrating the tumour, leading the authors to conclude that
NK cells do not play an important role in anti-tumour
immunity in brain cancer. Similar results were obtained by
Vaquero et al. for brain metastases [40] with use of the
IOT-10 antibody that also recognises CD57. In addition,
they showed that the degree of NK cell infiltration varied
depending on the origin of metastasis. In a recently pub-
lished work, the same group reported no correlation of the
degree of CD57? NK cells with the clinical outcome of
patients with brain metastasis [41]. The critical point of all
those studies is that the CD57 marker is expressed only on
a subset of NK cells and is also expressed on a significant
fraction of T cells [42]. Therefore a more precise analysis
is needed to determine the true frequency and degree of NK
cell infiltration in brain tumours.
Contrasting results were reported by Yang et al. [43] in
the most recently published work investigating immune cell
infiltrates in glioblastomas and comparing it with pilocytic
astrocytomas. According to their report, NK cells frequently
infiltrated the glioblastomas, whereas this infiltration was
negligible in pilocytic astrocytomas. Therefore, contrary to
Stevens et al. [39], the authors concluded that NK cells may
play an important role in anti-tumour immune responses in
glioblastoma patients. In this study the NK cells were
identified as CD56? cells. This method alone might give
inaccurate results as CD56 is also expressed by some
cytotoxic T cells [44]. According to our observations, NK
cells were one of the least numerous immune cell popula-
tions of all tumour infiltrating immune cells in glioblasto-
mas (2.11 % ± 0.54, mean ± SEM) and were
predominantly CD56dimCD16- [45]. These results are
based on multicolour flow cytometric phenotyping of
patients’ glioblastoma (GBM) tumour biopsies. The NK
cell population was defined as CD3 negative CD56 positive.
Concerning oligodendrogliomas, Rossi et al. reported
absence of NK cells in those tumours [46]. However, they
evaluated the expression of Leu11b (CD16) that is
expressed only on the major subpopulation of NK cells. In
Table 1 NK cell infiltration in intracranial tumours: summary of reviewed literature
Authors Tumour type Method, antibodies Degree of NK cell infiltration Distribution of NK cells
in the tumour tissue
Stevens et al. [39] Gliomas grade IV IHC, Leu7 and Leu11b Low Within perivascular
cuffs
Gliomas grade I–II No infiltration
Carcinoma metastases Intermediate Around blood vessels
and within tumour
parenchyma
Craniopharyngiomas Intense No specific distribution
Meningiomas Low –
Other tumours Low –
Vaquero et al. [40] Brain metastases IHC, IOT-10 Less than 10 % of TILs in most
cases (39/40)
Mainly associated with
vessels and stroma
Yang et al. [43] Glioblastomas IHC, CD56 Perivascular: intermediate or
extensive in app.70 % cases;
Intratumoural: intermediate in
app. 25 % cases, none in app.
50 % cases
Mostly perivascular/
extratumoural
Pilocytic astrocytoma No infiltration
Rossi et al. [46] Oligodendrogliomas IHC, Leu11b No infiltration
Domingues et al. [47] Meningiomas Flow cytometry, NK
cell population
defined as CD3-
CD19-CD56?
0.2 ± 0.3 % of all cells
IHC immunohistochemistry, TIL tumour-infiltrating lymphocytes, – no data reported
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the light of the observations made by Stevens et. al [39],
who did not detect Leu11b positive cells despite the pre-
sence of Leu7 (CD56) positive infiltrates in various brain
tumour specimens and our own studies that did not detect
CD16 positive NK cells in GBMs, it is possible that in
oligodendrogliomas a similar expression pattern of
CD56?CD16- occurs as in the other gliomas.
The most recent study focusing on meningiomas was
conducted by Domingues et al. [47] and demonstrated the
presence of NK cells within the tumour. Similar to our
results and those of Stevens et al., [39], NK cells were one
of the least numerous immune cell populations infiltrating
the tumour.
Are NK cells a potent anti-tumour agent against brain
cancer? Functional studies
A number of in vitro and in vivo functional studies have
been performed in order to investigate the role of NK cells
in anti-tumour immunity in brain cancers and the potential
of using them as a therapeutic agent. Alizadeh et al. [28]
investigated the therapeutic efficacy of a toll-like receptor 9
(TLR9) ligand, CpG-oligodeoxynucleotides (CpG-ODN),
in vivo in a murine glioma model. They showed that NK
cell numbers in brain, blood and spleen decreased with
tumour growth, possibly as a result of tumour-induced
immunosuppression. However, they also demonstrated that
the therapy they used against glioma induced host immune
responses and NK cells mediated the resistance to tumour
re-challenge. Another group demonstrated increased cyto-
toxic activity of splenic NK cells isolated from glioblas-
toma-bearing animals treated with recombinant adeno-
associated virus 2 encoding IL-12 [48]. Dendritic cell (DC)
vaccination has also been shown to stimulate IFNc secre-
tion by NK cells and increase their number in the periph-
eral blood in GBM patients [49]. On the other hand,
Alvarez-Breckenridge et al. showed in vivo, that NK cells
can negatively influence virotherapy against glioblastoma
[31]. Castriconi et al. [25] evaluated the susceptibility of
the glioblastoma stem-like cells to NK cell-mediated lysis
in vitro. They found that both allogeneic and autologous
activated NK cells were able to efficiently kill the GBM
cells. However, the GBM cells were resistant to resting NK
cells. Avril et al. [26] compared the GBM cells cultured
under serum-free conditions with those serum-cultured in a
series of cytotoxicity assays using activated NK cells and T
cells as effectors. They reported that GBM stem-like cells
were more susceptible to both NK cell- and T cell-medi-
ated lysis. Moreover, they showed that in combination with
the therapeutic antibody cetuximab, NK cells were able to
kill GBM stem-like cells via ADCC. Our team recently
demonstrated that combination treatment with NK cells
?mAb9.2.27 against the NG2/CSPG4 proteoglycan dimin-
ished tumor growth that was associated with reduced tumor
proliferation, increased cellular apoptosis and prolonged
survival compared to vehicle and monotherapy controls.
Therapeutic ADCC was mediated by recruitment of
CCR2low macrophages into the tumor microenvironment,
increased ED1 and MHC class II expression on microglia
that rendered them competent for GBM antigen presenta-
tion, as well as elevated IFN-c and TNF-a levels in the
cerebrospinal fluid compared to controls [29]. The advan-
tages and relevance of these studies were the use of purified
NK cells and patient-derived GBM cells.
Can the anti-tumour potential of NK cells be exploited
in the clinic?
The prognostic significance of NK cells’ activity has been
demonstrated in patients with various solid tumours
[20–22, 24]. A higher level of CD57 positive cells infil-
tration into the tumour correlates with better survival of
patients with oesophageal squamous cell carcinoma [20],
squamous cell lung cancer [24] and gastric carcinoma [21].
As mentioned before, CD57 is expressed also on a subset
of T cells [42], therefore very likely both NK cells and T
cells contribute to better patient outcomes. In the study of
Kondo et al., a high activity of peripheral NK cells posi-
tively correlated with longer survival of colon cancer
patients [22]. They also observed that cumulative 5-year
metastasis-free rates were higher in the group of patients
with high NK cell infiltration (90 vs. 60 %). These data
suggest NK cells play an important role in controlling
metastases. Moreover, tumour cells have been shown to
express ligands for activating receptors expressed on NK
cells [50, 51], making them potentially susceptible to NK
cell-mediated lysis. Various immunotherapies against brain
cancer have been tested so far (reviewed in [52]), including
DC vaccination, adoptive T cell transfer, and transfer of
lymphokine activated killer (LAK) cells. Most of the
clinical trials referring to NK cell activity utilized autolo-
gous LAK cells combined with IL-2 injections (recently
reviewed in [53]. LAK cells are obtained from peripheral
blood mononuclear cells (PBMCs) cultured at conditions
that stimulate their expansion and activation. The final
product is a mixture of T cells (majority of them are
cytotoxic T lymphocytes (CTLs) and NK cells. Those trials
demonstrated partial efficacy and moderate adverse effects
(mostly edema) [54, 55]. The weak point of those studies is
that the effector cell populations contributing to anti-gli-
oma effect have not been characterised and the mecha-
nisms of treatments tested have not been investigated.
However, they showed the potential of cellular therapy
against the most malignant brain tumour.
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Therefore, using pure NK cells against solid tumours
becomes an attractive alternative strategy to using LAK
cells. To date, only one phase I clinical trial has been
conducted, where pure autologous NK cells were used as
effector cells against brain tumours [30]. In this study, 9
patients with recurrent malignant glioma received intra-
cranial or intravenous injection of NK cells expanded from
patients’ PBMCs. In 4 of 9 patients, the tumour regression
was recorded as magnetic resonance imaging (MRI)
radiological response. The benefit in terms of survival
outcomes was not evaluated. The authors concluded their
therapy was less toxic but was as efficient as LAK cells
combined with IL-2. The lower toxicity might be due to the
considerably lower doses of IL-2 used. The limited efficacy
of experimental therapies utilizing autologous LAK or NK
cells might be due to the local and highly integrated tumour-
induced immune suppression and immune escape mecha-
nisms. CTLs require antigen presentation and co-stimula-
tion signals that are often impaired in brain tumour patients
[45]. Our group has also demonstrated that GBM cells
highly express MHC class I molecules [45], that are ligands
for inhibitory receptors expressed on NK cells [12].
Therefore, engaging NK cells to kill the tumour cells might
require additional, combination treatments that will
enhance their activity and/or overcome tumour immune
escape mechanisms. One possibility is the use of tumour
specific antibodies that would induce ADCC mediated by
engaging the FccRIIIA receptor (CD16) on NK cells
(Fig. 1a). An interesting approach investigated in other
solid tumours is the use of fusion proteins comprised of a
part recognising the tumour-specific antigen conjugated to a
ligand for activating NK cell receptors, like NKG2D
(Fig. 1b) [56]. However, these two strategies are of limited
use in the highly heterogeneous brain tumours. There rarely
exist in these malignancies tumour-specific antigens that are
expressed on all the tumour cells in each patient and that are
also absent on the normal cells. Moreover, it may be
envisaged that these tumours would eventually escape the
treatment by developing antigen loss variants. Reducing
NK cell inhibition mediated by interactions of inhibitory
KIR receptors with human leukocyte antigen (HLA) ligands
may be achieved by blocking KIR receptors with specific
antibodies (Fig. 1c). This strategy has been tested in mul-
tiple myeloma patients and proved to be safe [57]. Another
alternative solution would be the use of allogeneic NK cells
instead of patients’ own cells (Fig. 1d). The allogeneic NK
cells have been shown to mediate the graft versus leukemia
(GvL) effect in haematological malignancies [58]. The
hypothesized mechanism is the receptor-ligand mismatch
between the KIR receptors expressed on donor’s NK cells
and cognate HLA ligands expressed by recipient’s cells
resulting in the absence of inhibitory signals mediated by
KIR receptors expressed by a subpopulation of NK cells
[59]. Moreover, the patient’s normal cells are spared from
killing due to the absence of activating ligands that are
expressed almost exclusively on transformed cells. We
hypothesise that the same strategy could be used in the
treatment of solid tumours, including brain cancer. More-
over, a combination of autologous or allogeneic NK cell-
Fig. 1 Treatment strategies for using NK cells against brain tumours.
a Therapeutic antibodies, such as cetuximab (anti-EGFR antibody)
can induce antibody-dependent cellular cytotoxicity (ADCC) medi-
ated by FccRIIIA receptor (CD16) expressed on NK cells. b Immu-
noligand is a fusion protein: the part recognising specific antigen is
conjugated to ligand for activating receptor. Immunoligand binds
tumour-specific antigen and stimulates NK cells (endogenous and/or
transferred, both autologous and allogeneic) via interaction with
activating receptor (e.g. NKG2D). c Applying KIR-blocking antibody
reduces the inhibition of both endogenous NK cells as well as
adoptively transferred autologous NK cells. d Transfer of allogeneic
NK cells with KIR-HLA mismatch approach. Lack of recognition of
tumour’s HLA by inhibitory KIR receptors results in the absence of
inhibitory signals and NK cell activation. ? activating receptor,
L ligand
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based cellular therapy with immune stimulating treatment
such as inhibitory KIR-blocking antibody could give better
results compared to each of those strategies applied alone.
Brain tumour patients could also benefit from combining
adoptive transfer of NK cells with already approved thera-
peutic antibodies such as cetuximab, an anti-epidermal
growth factor receptor (EGFR) antibody. Figure 2 sum-
marizes the potential of combination approaches and the
role of NK cells in anti-tumour immune response.
Conclusions and perspectives: why do we need further
investigation in this field?
The NK cells have limited access into the nascent brain [60]
and they are the least abundant immune cell population
within the brain tumour microenvironment. However, dif-
ferent methods used to detect NK cells in the tumour tissue
led to conflicting results. Recent developments give an
opportunity to study the infiltration of NK cells with more
precise methods, such as with NK cell-specific antibodies or
with multicolour flow cytometry with a panel of markers. It
is also important to reveal the mechanism of NK cell
recruitment, as various experimental therapeutic agents
have been demonstrated to stimulate NK cell-mediated anti-
tumour immune responses [8, 27, 28, 32]. NK cells might
also influence the efficacy of other anti-cancer treatments
[31], therefore their translation into clinic requires knowl-
edge about the patients’ immunological status.
Malignant brain tumours develop multiple mechanisms
of immune escape and both local, and systemic immuno-
suppression [33, 36, 45, 61, 62]. Many immunotherapies
are based on patients’ own immune cells isolated from
peripheral blood. Therefore, it is of great importance to
investigate the functionality of autologous NK cells in
brain tumour patients and the tumour-derived factors that
Fig. 2 The interplay of NK and other immune cells in anti-tumour
responses. Endogenous and/or adoptively transferred autologous NK
cells can be stimulated by immunoligands (1) and/or KIR blocking
antibodies (2). Therapeutic antibodies such as cetuximab (anti-EGFR
antibody) can induce antibody-dependent cellular cytotoxicity
(ADCC) (3). Other possible strategy is cellular therapy with allogeneic
NK cells with KIR-HLA mismatch approach (graft vs. tumour effect,
GvT) (4). Stimulated and/or alloreactive NK cells are able to directly
kill the tumour cells, as well as to secrete pro-inflammatory cytokines
such as IFNc to further stimulate other immune cells: macrophages,
microglia (5) and T cells (6). NK cells may play an important role in DC
vaccination due to DC-NK cell cross-talk further stimulating anti-
tumour immune response (7). Stimulated macrophages, microglia and
DC can present tumour-associated antigens (8) and induce CTLs-
mediated cytotoxicity (9). ? activating receptor, L: ligand
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could negatively influence NK cell-based therapy. So far,
very few studies have been conducted and most of them
investigated whole lymphocyte populations [33]. Research
focused on pure NK cell fractions could facilitate the
development of efficient treatment strategies directly uti-
lizing NK cells as anti-cancer agents or stimulating
endogenous NK cells.
To summarize, NK cells play an important role not only
in anti-tumour immunity but they are potent effectors that
may be considered for developing novel immunotherapies.
However, stringent research is required to determine the
impact of NK cell infiltration into the tumour site and their
therapeutic efficacy in brain tumour patients. Investigating
NK cells in the context of brain tumour is also essential for
improving the NK cell-based immunotherapies that are
increasingly investigated for clinical development for brain
tumour patients.
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